| 49th week of 2010 patent applcation highlights part 37 |
| Patent application number | Title | Published |
|---|
| 20100310499 | LURE - The invention relates to a lure for attracting, and in some circumstances, killing dust mites, especially house dust mites. The lure comprises neryl formate and/or limonene and is usually arranged in powder form to allow it to be shaken over an area containing the mites. What about liquid that dries. | 2010-12-09 |
| 20100310500 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS - The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 2010-12-09 |
| 20100310501 | Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian Subject - A method for increasing a biological activity of a cytokine or lymphokine and a method of treating a neoplastic disease, autoimmune disease, or infectious disease, and a method for expanding a hematopoietic cell population, is provided by administering an antibody capable of binding a cytokine or by administering a cytokine complexed with an antibody or by administering a cytokine complexed with a cytokine receptor to a mammalian subject in need thereof. | 2010-12-09 |
| 20100310502 | Method of treating local infections in mammals - An effective method is provided for local treatment against localized microbial infection, including abscesses, in skin and soft tissue and elsewhere in mammalian organs. The method employs mammalian IL-17 receptor agonists, which exert several antimicrobial actions, including the stimulation of neutrophil turnover as well as macrophage phagocytosis locally in an infected mammalian organ. | 2010-12-09 |
| 20100310503 | NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT - The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer. | 2010-12-09 |
| 20100310504 | METHODS FOR TREATING FIBROSIS BY MODULATING CELLULAR SENESCENCE - Fibrosis arises as part of a wound healing response that maintains organ integrity following catastrophic tissue damage, but can also contribute to a variety of human pathologies, including liver cirrhosis. The invention demonstrates that cellular senescence acts to limit the fibrogenic response to tissue damage, thereby establishing a role for the senescence program in pathophysiological settings beyond cancer. Accordingly, the methods of the invention relate to modulating cellular senescence in disease tissue that have elevated numbers of senescent cells, such as in fibrotic tissues. | 2010-12-09 |
| 20100310505 | METHODS OF TREATING CANCER USING IL-21 - Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics. | 2010-12-09 |
| 20100310506 | Immunoconjugates for the Treatment of Tumours - A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism. | 2010-12-09 |
| 20100310507 | USE OF 2 ANTI-SPARC ANTIBODIES TO PREDICT RESPONSE TO CHEMOTHERAPY - The invention provides anti-SPARC antibody-based techniques for predicting a response to chemotherapy. | 2010-12-09 |
| 20100310508 | METHODS OF TREATMENT INVOLVING p21/CIP1 - The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p16 | 2010-12-09 |
| 20100310509 | COMPOSITIONS COMPRISING MODULATORS OF SIGNAL TRANSDUCING RECEPTOR gp130 AND METHODS OF PRODUCING AND USING SAME - Compositions comprising modulators of gp130, as well as methods of producing and using same, are disclosed. | 2010-12-09 |
| 20100310510 | N-TERMINALLY CHEMICALLY MODIFIED PROTEIN COMPOSITIONS AND METHODS - Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon. | 2010-12-09 |
| 20100310511 | DETERMINING DISEASE OR IMMUNE SYSTEM FEATURES BASED ON ANALYSIS OF IMMUNE SYSTEM CHARACTERISTICS - Methods for analyzing one or more elements, markers, ligands or other characteristics of the immune system of a body (e.g., of a human or other animal), and based on the analysis, determine a location of disease, identify immune system failure, and/or determine treatments based on disease location or immune system failure. All or a part of the immune system process may be analyzed to identify specific features of the immune system, e.g., which may indicate that the disease will evade the immune system and produce a negative outcome. Therapy may be employed to correct immune system failure rather than addressing the disease directly. | 2010-12-09 |
| 20100310512 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2010-12-09 |
| 20100310513 | BIFIDOBACTERIAL SPECIES - New bacterium GC61 belonging to the genus | 2010-12-09 |
| 20100310514 | Anti-Inflammatory Bacteria - Lactic acid bacteria expression cathelicidin, and methods of their use, are provided. | 2010-12-09 |
| 20100310515 | Latency Associated Protein Construct With Aggrecanase Sensitive Cleavage Site - The present provides a fusion protein comprising a latency associated peptide (LAP) and a pharmaceutically active agent in which the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising an aggrecanase proteolytic cleavage site. | 2010-12-09 |
| 20100310516 | Duplexed Parvovirus Vectors - The present invention provides duplexed parvovirus vector genomes that are capable under appropriate conditions of forming a double-stranded molecule by intrastrand base-pairing. Also provided are duplexed parvovirus particles comprising the vector genome. Further disclosed are templates and methods for producing the duplexed vector genomes and duplexed parvovirus particles of the invention. Methods of administering these reagents to a cell or subject are also described. Preferably, the parvovirus capsid is an AAV capsid. It is further preferred that the vector genome comprises AAV terminal repeat sequences. | 2010-12-09 |
| 20100310517 | GROWTH FACTOR MEDIATED COSMECEUTICALS AND USE THEREOF TO ENHANCE SKIN QUALITY - It has been discovered that vascular endothelial growth factor (“VEGF”) promotes migration of activated (but not differentiating) keratinocytes to skin. This growth factor specifically increases migration of keratinocytes of the “wounded skin” phenotype but does not have significant effects upon differentiated keratinocytes. It also increases collagen deposition and reduces wrinkles, enhances skin quality, and increases skin thickness to normal levels in individuals where skin has thinned due to age or disorder such as diabetes. It is particularly well suited for use as cosmeceuticals when applied in purified form and in known amounts. The data presented in the examples demonstrate efficacy and specificity of VEGF in enhancing migration of normal human keratinocytes as well as formation of new granulation tissue including collagen formation. VEGF induces keratinocyte and fibroblast migration, formation of new tissue, and not only induces deposition of collagen but improves alignment of the collagen fibers. Accordingly, this growth factor is highly suitable for use as a cosmeceutical, especially for skin resurfacing and reduction in wrinkles. | 2010-12-09 |
| 20100310518 | Combinations of Flubendiamide and Beneficial Species - The novel combinations of flubendiamide and beneficial species comprising flubendiamide and at least one beneficial species from the orders or suborders of the Araneae, Acari, Dermaptera, Hymenoptera, Coleoptera, Neuroptera, Thysanoptera, Heteroptera, Diptera, Hemiptera, Dermaptera and/or Parasitiformes or at least one bacteria strain or at least one virus strain for the effective control of unwanted pests. | 2010-12-09 |
| 20100310519 | Incorporation of Active Molecules into Microalga - Process of incorporating active and aggressive molecules into a microalga, with targeted recognition of cancer cells. The invention relates to the incorporation of active molecules into a microalga having first developed a plasmid, and/or a gene with resistance to the specific molecules. The process of the invention is particularly intended for human and veterinary medicine. | 2010-12-09 |
| 20100310520 | MICROORGANISMS FOR IMPROVING THE HEALTH OF INDIVIDUALS WITH DISORDERS RELATED TO GLUTEN INGESTION - The invention relates to microorganisms for the treatment of food allergies, specifically coeliac disease, as well as to methods for the selection thereof. The action mechanisms of said microorganisms include: (i) the regulation of the innate and adaptive immunological responses; (ii) the reduction of the concentration of toxic gluten peptide epitopes in the intestinal lumen; (iii) the strengthening of the barrier defence function against harmful antigens and bacteria; and (iv) the provision of enzymatic activities that promote digestion. | 2010-12-09 |
| 20100310521 | POLYNUCLEOTIDE SEQUENCE FOR THE INHIBITION OF PHOSPHOLAMBAN SYNTHESIS - A DNA polynucleotide sequence is disclosed that comprises a transcribed sequence, and a promoter sequence. Transcription of the transcribed sequence by an RNA polymerase in a cell renders an RNA a transcript capable of forming a partially self-complementary hairpin structure which can be processed by the cell to an siRNA product that can degrade phospholamban mRNA in such cell. The promoter is a drug inducible conditional promoter or a cardiomyocyte cell-specific promoter or both, operably linked to the transcribed sequence. The promoter is operable by an RNA polymerase naturally occurring in a mammalian cell. | 2010-12-09 |
| 20100310522 | Novel Polypeptides Having Endolysin Activity and Uses Thereof - The present invention provides isolated polypeptides comprising the amino acid sequence of SEQ ID NO:1, or a fragment, variant, derivative or fusion thereof which is capable of binding specifically to and/or lysing cells of | 2010-12-09 |
| 20100310523 | Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene - There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention. | 2010-12-09 |
| 20100310524 | Compositions Suitable for Treatment of Spinal Disease, Disorder or Condition - The invention relates to the use of viral inactivated-plasma cryoprecipitate concentrate (VIPCC) comprising a suitable fibronectin/fibrinogen ratio for treating a spine disease, disorder or condition such as intervertebral disc degeneration. | 2010-12-09 |
| 20100310525 | WNT PATHWAY STIMULATION IN REPROGRAMMING SOMATIC CELLS - The invention provides compositions and methods of use in reprogramming somatic cells. Compositions and methods of the invention are of use, e.g., for generating or modulating (e.g., enhancing) generation of induced pluripotent stem cells by reprogramming somatic cells. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a pluripotent state and/or enhances the speed and/or efficiency of reprogramming. Certain of the compositions and methods relate to modulating the Wnt pathway. | 2010-12-09 |
| 20100310526 | COSMETIC METHOD FOR INCREASING THE PIGMENTATION OF SKIN USING MELANOCYTE PRECURSOR CELLS - The present invention proposes a cosmetic method for increasing the pigmentation of skin with the steps application of melanocyte precursor cells from root sheaths collected from a first area of skin of a donor to a second area of skin of a recipient. Furthermore, the use of melanocyte precursor cells for increasing the pigmentation of skin as well as a method for producing a suspension having precursor cells from the root sheath is proposed. | 2010-12-09 |
| 20100310527 | LIPOSOME MEDIATED DELIVERY OF LINEAGE DETERMINING FACTORS - Methods and compositions are provided for lineage predetermination of cellular transplants including through liposome mediated transfection with aqueous protein extracts from populations of differentiated mammalian cells, or cellular fractions thereof, wherein the differentiated mammalian cells are enriched in one or more of adipocytes, chondrocytes, endothelial cells, hepatocytes, cardiomyocytes, smooth muscle cells, skeletal muscle cells, cardiac pacemaker cells, Schwann cells, pancreatic islet cells, hematopoietic cells, myeloblasts, neurons, and osteoblasts. | 2010-12-09 |
| 20100310528 | Vector System for Site-Specific Integration - The integration system comprises at least one vector capable of expressing at least one exogenous gene, the vector comprising a coding sequence for an attP gene region and a coding sequence for at least one therapeutic molecule and an integrase. The integration system has an application in bacterial metabolic engineering and in gene therapy. | 2010-12-09 |
| 20100310529 | EXTRACELLULAR MATRIX FROM PLURIPOTENT CELLS - Isolated extracellular matrix from marrow adherent stromal cells and their descendents, which stimulates the growth and survival of a number of different neural cell types, is provided, along with methods for preparation and uses. | 2010-12-09 |
| 20100310530 | Cell Therapy for Brain Tissue Damage - Disclosed are methods for conditioning stems cells and using the conditioned stems cells for treating brain tissue damage. | 2010-12-09 |
| 20100310531 | PEPTIDE-COATED CELL LOCALIZATION TO DISEASED OR DAMAGED TISSUES AND METHODS RELATED THERETO - Embodiments of the present invention are directed to a coated cell comprising a therapeutic cell and a plurality of targeting complexes coating the therapeutic cell and each of said targeting complexes comprising a homing molecule, a lipid moiety, and a spacer having from about 1 to about 10 amino acids and covalently linking the homing molecule to the lipid moiety and wherein the lipid moiety is non-covalently attached to the therapeutic cell. In some embodiments, the therapeutic cell is a stem cell. Embodiments of the invention are directed to methods of coating a therapeutic cell. Embodiments of the invention are directed to methods of treating diseases of the vasculature. | 2010-12-09 |
| 20100310532 | GENE TARGETS IN ANTI-AGING THERAPY AND TISSUE REPAIR - Novel gene and protein targets are described for treatment of cardiac disorders, anti-aging therapies and tissue repair. Identified biomarkers are prognostic of long term survival of patients suffering from heart diseases and related disorders. | 2010-12-09 |
| 20100310533 | METHODS OF USING IL-21 FOR ADOPTIVE IMMUNOTHERAPY AND IDENTIFICATION OF TUMOR ANTIGENS - Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material. | 2010-12-09 |
| 20100310534 | T CELL SUBPOPULATIONS CAPABLE OF TREATING CANCER - A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8 | 2010-12-09 |
| 20100310535 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND - An object of the present invention is to expand CD34 | 2010-12-09 |
| 20100310536 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND - An object of the present invention is to expand CD34 | 2010-12-09 |
| 20100310537 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND - An object of the present invention is to expand CD34 | 2010-12-09 |
| 20100310538 | USE OF R(+)-ALPHA-LIPOIC ACID FOR CRYPTOGENIC NEUROPATHY - The present invention relates to the use of R(+)-alpha-lipoic acid ((R)-5-(1,2-dithiolan-3-yl)valeric acid) and/or of a physiologically acceptable derivative of this compound for cryptogenic neuropathy. | 2010-12-09 |
| 20100310539 | METHOD FOR MANUFACTURING MESOPOROUS MATERIALS, MATERIALS SO PRODUCED AND USE OF MESOPOROUS MATERIALS - The present invention relates to a new synthetise for the preparation of mesoporous structures including mesoporous materials with chiral morphologies and mesoporous materials with local or surface chirality. The method can be used for manufacturing controlled drug delivery devices, for example for delivery of folic acid, and fluorescent particles. | 2010-12-09 |
| 20100310540 | METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE TAFIA ACTIVITY, COMPOUNDS, AND METHODS OF USING THE COMPOUNDS - Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites. Also contemplated is a method of treating, preventing or managing in a patient, pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder comprising administering aspirin or a derivative thereof or any other therapeutic having at least one desired therapeutic or prophylactic activity of aspirin to a patient in need thereof and administering to the patient a factor that promotes TAFIa activity, e.g. stabilized TAFIa, to ameliorate one or more adverse side effects of the therapeutic. Compounds identified by the methods of the invention are also provided. | 2010-12-09 |
| 20100310541 | Compositions and Methods for Reducing the Toxicity of Certain Toxins - Compositions and methods for reducing the toxic effect of certain peptide toxins by administering an agent that directly or indirectly reduces disulfide bonds that are important for maintaining the toxin in an active conformation. Also described are compositions and methods for reducing the toxic effect of toxins that contain a heavy metal using an agent that destabilizes the binding of a metal ion that is important for toxin activity. | 2010-12-09 |
| 20100310542 | Pharmaceutical Compositions for treating wouds and related methods - The present disclosure relates to compositions and methods for accelerating the healing process of wounds, increasing the closure of skin wounds, and decreasing inflammation at the site of a skin wound. Specifically, the disclosure relates to compositions comprising a delta-PKC activator, an alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that is free of Ca | 2010-12-09 |
| 20100310543 | METHOD OF PREVENTING AND TREATING ACUTE BRAIN PATHOLOGIES - Described are novel means in the treatment of cerebral neurological conditions such as ischemic insult of the brain. Furthermore, a kit for a non-radioactive protein serine/threonine phosphatase activity assay is provided, which is capable of detecting and distinguishing the activity of PP1, PP2A, and calcineurin (PP2B). | 2010-12-09 |
| 20100310544 | COMPOSITION COMPRISING CALCIUM IONS AND AT LEAST ONE PROTEOLYTIC ENZYME FOR USE IN THE IN VITRO AND IN VIVO REGENERATION OF CUTANEOUS AND CONNECTIVE TISSUES - The invention is based on the finding that calcium ions and proteolytic enzymes, particularly papain, act in a synergetic way in the regeneration of skin and connective tissues. Thus, such a combination of active principles can be used for the preparation of culture media for cutaneous and/or connective tissue biopsies, which allow for the maintenance of the biopsies under viable conditions for periods of over 6 months, even for over 3 years, as well as for the preparation of pharmaceutical compositions or medical devices for the treatment of diseases in which the regeneration of cutaneous and connective tissues is beneficial (for instance, injuries and wounds, keloids, paradontopathies, conjunctivitis, nasal and ear polyps, cellulite, human and animal dermatitis), and for the preparation of cosmetic compositions that in particular have an anti-ageing effect on the skin. | 2010-12-09 |
| 20100310545 | Dry treatment mixture and methods of production and use - A dry treatment mixture is provided including: a quantity of a dry formulation of a salt; and a quantity of a dry formulation of lysozyme. The salt preferably is sea salt. The dry treatment mixture preferably additionally includes a dry formulation of lactoferrin. A method of producing a dry treatment mixture preferably includes the steps of: providing a quantity of a dry formulation of salt in one of powder form and granular form; providing a quantity of a dry formulation of lysozyme; and mixing the quantity of a dry formulation of salt and the quantity of a dry formulation of lysozyme together to form a dry treatment mixture. The method optionally includes the yet additional step of compressing a quantity of the mixture in a mold to form a mixture pill or of encapsulating the quantity of the mixture in a capsule for oral administration, or impregnating a bandage with the mixture for topical administration. | 2010-12-09 |
| 20100310546 | ACE2 Polypeptide - The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life. | 2010-12-09 |
| 20100310547 | Treatment of Inflammatory Diseases - The present invention relates generally to the field of inflammatory diseases of the peripheral nervous system. More particularly, it concerns methods for treating inflammatory diseases of the peripheral nervous system by modulating sphingosine-1-phosphate receptor activity. In one embodiment, the present invention provides a method of treating a subject with chronic inflammatory demyelinating polyneuropathy (CIDP) or other autoimmune neuropathies comprising administering to the subject an effective amount of FTY720. | 2010-12-09 |
| 20100310548 | Methods of Manufacturing a Biologic Using a Stable Storage Intermediate - The present invention is directed to methods of isolating and purifying protein from a bioreactor process. The invention relates to employing a protein phase separation methodology to isolate or purify protein product in the forms of solid, semi-solid, or suspension during a protein manufacturing purification process as a stable storage intermediate. This approach is designed to allow the isolated protein product (purified or partially purified) to be stored over an extended period of time prior to further protein purification steps. | 2010-12-09 |
| 20100310549 | INHIBITORS OF TYPE 2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS - The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides. | 2010-12-09 |
| 20100310550 | ALPHA 1- ANTITRYPSIN COMPOSITIONS - A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described. | 2010-12-09 |
| 20100310551 | IMMUNOGENIC, MONOCLONAL ANTIBODY - The invention relates to an immunogenic antibody which comprises at least two different epitopes of a tumor-associated antigen. | 2010-12-09 |
| 20100310552 | Antibodies produced in the avian oviduct - The invention relates to transgenic avians which produce antibodies in the egg white by introducing a nucleic acid sequence into the genome of an avian embryo wherein the nucleic acid sequence comprises a nucleotide sequence encoding an antibody and to the antibodies and to methods related thereto. | 2010-12-09 |
| 20100310553 | Compositions and Methods for Controlling Hepatitis C Virus Infection - Disclosed herein are methods and compositions for the treatment and prevention of Hepatitis C Virus (HCV) infection and methods of screening for antiviral agents against HCV infection and/or production. A method of using compositions of certain apolipoprotein-specific monoclonal or polyclonal antibodies to inhibit HCV infectivity is disclosed. Further, methods of using small interfering RNAs (siRNAs) specific to apolipoproteins for treating and/or preventing HCV infection are disclosed. Also disclosed are methods of using siRNAs specific and/or small molecule inhibitors to certain lipoprotein biosynthetic genes and of using recombinant apolipoprotein E and/or their forms of lipoproteins to treat and/or prevent HCV infections. Screening methods for anti-HCV agents include assessing the effect of a candidate agent on apolipoprotein E and/or apolipoprotein C-I gene expression, assembly, and/or secretion and assessing the effect of a candidate agent on the blockage of the interaction and/or incorporation of HCV nonstructural proteins and/or their fusion forms with reporter proteins into HCV virions. | 2010-12-09 |
| 20100310554 | Methods for Reversing Multiple Resistance in Animal Cells - The present invention is related to the use of a virus, preferably an adenovirus for reversing resistance in cells. | 2010-12-09 |
| 20100310555 | COMPOSITIONS WITH HEMATOPOIETIC AND IMMUNE ACTIVITY - The present invention provides methods of using Bv8 and EG-VEGF polypeptides and nucleic acids to promote hematopoiesis. Also provided herein are methods of screening for modulators of Bv8 and EG-VEGF activity. Furthermore, methods of treatment using Bv8 and EG-VEGF polypeptides or Bv8 and EG-VEGF antagonists are provided. | 2010-12-09 |
| 20100310556 | THERAPEUTIC AGENT FOR PRURITUS - The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba/F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus. | 2010-12-09 |
| 20100310557 | ANTIBODIES IMMUNOREACTIVE WITH HEREGULIN-COUPLED HER3 - Antibodies which specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer. | 2010-12-09 |
| 20100310558 | Method for Linking Sequences of Interest - Multiplex overlap-extension RT-PCR provides an efficient method of linking two or more nucleotide sequences encoding for domains or subunits of a heteromeric protein, in a single reaction. Especially, the linkage of variable region encoding sequences from e.g. immunoglobulins, T cell receptors or B cell receptors is eased with the method of the present invention. This allows for a more efficient way of generating libraries of variable region encoding sequences. The capability to perform the multiplex overlap-extension RT-PCR using template derived from an isolated single cell enables the generation of cognate pair libraries in a high-throughput format. | 2010-12-09 |
| 20100310559 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS - The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences. | 2010-12-09 |
| 20100310560 | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR | 2010-12-09 |
| 20100310561 | NATRIURETIC FUSION PROTEINS - Natriuretic peptide fusion proteins comprising natriuretic peptides linked to antibody Fc domains, nucleic acid molecules encoding the fusion proteins disclosed herein, expression vectors expressing said fusion proteins, pharmaceutical compositions comprising said fusion proteins, and methods for their therapeutic use are disclosed. | 2010-12-09 |
| 20100310562 | SYSTEM FOR DELIVERY INTO XCR1 POSITIVE CELL AND USES THEREOF - The present invention relates to a delivery system suitable for delivering a substance into a XCR1 positive professional antigen-presenting cell, one or more nucleic acids coding for the same, a vector comprising the nucleic acid(s), a medicament comprising the delivery system or the one or more nucleic acid(s) and an adjuvant comprising XCL1 or a functionally active fragment thereof. | 2010-12-09 |
| 20100310563 | METHODS FOR TREATING INDUCED CELLULAR PROLIFERATIVE DISORDERS - Methods are provided for treating a subject with a cellular proliferative disorder that include administering to the subject a therapeutically effective amount of a JAK2 inhibitor and a therapeutically effective amount of a TNF-alpha inhibitor. In addition, methods are provided herein for determining if a subject with a cellular proliferative disorder would benefit from treatment with an agent that inhibits tumor necrosis factor (TNF)-alpha. Methods are also provided for identifying an agent of use in treating a subject with a cellular proliferative disorder or with a predisposition for cellular proliferative disorder. The methods include contacting an isolated cell expressing an activating mutation in the JAK2 protein with a test agent, and detecting the amount of tumor necrosis factor (TNF)-alpha produced by the cell. | 2010-12-09 |
| 20100310564 | Method for the Treatment of Glomerulonephritis - The present invention provides a method for the treatment and/or prophylaxis of glomerulonephritis associated with one or more disorders selected from the group consisting of Goodpasture's syndrome, a vasculitic disorder, Wegener's disease, IgA nephropathy and an inflammatory disease with basement membrane involvement comprising administering a therapeutically effective amount of agent which interacts with or modulates the expression or activity of a mammalian IL-6 polypeptide. | 2010-12-09 |
| 20100310565 | ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME - The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation. | 2010-12-09 |
| 20100310566 | Fibroblast Growth Factor-Like Polypeptides - The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides. | 2010-12-09 |
| 20100310567 | Antibodies Against Human CCN1 and Uses Thereof - Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases. | 2010-12-09 |
| 20100310568 | NINJURIN-1 MODULATION AND USES THEREOF - Methods, uses, agents and compositions useful for the prevention, treatment and/or diagnosis of neuroinflammatory conditions such as multiple sclerosis and spinal cord injury based on the modulation of nerve injury-induced protein-1 (Ninjurin-1) are disclosed. | 2010-12-09 |
| 20100310569 | Genes of an Otitis Media Isolate of Nontypeable Haemophilus Influenzae - The invention relates to the polynucleotide sequence of a nontypeable stain of | 2010-12-09 |
| 20100310570 | MAPC TREATMENT OF BRAIN INJURIES AND DISEASES - The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example. | 2010-12-09 |
| 20100310571 | USES OF MONOCLONAL ANTIBODY 8H9 - This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof. | 2010-12-09 |
| 20100310572 | Binding molecules capable of neutralizing rabies virus and uses thereof - Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from rabies virus. In certain embodiments, they can be used in the post-exposure prophylaxis of rabies. | 2010-12-09 |
| 20100310573 | ANTI-CD4 ANTIBODY - An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. | 2010-12-09 |
| 20100310574 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF STATIN-INDUCED MYOPATHY - The invention provides compositions and kits containing an atrogin-1 inhibitor compound useful for the treatment of a statin-mediated myopathy. Kits for the diagnosis of a statin-mediated myopathy are also provided. The invention further features methods for treating or preventing a statin-mediated myopathy in a subject via administration of a therapeutically effective amount of an atrogin-1 inhibitor compound. The invention further provides methods of diagnosing a subject as having a propensity to develop a statin-induced myopathy and methods of monitoring a statin-induced myopathy or a propensity to develop a statin-mediated myopathy in a subject. The invention also features methods for identifying a compound for the treatment of a statin-mediated myopathy and methods of identifying a statin compound as having the propensity to induce a statin-mediated myopathy. | 2010-12-09 |
| 20100310575 | Inhibitors of Caspase I-Dependent Cytokines in the Treatment of Neurodegenerative Disorders - The present invention relates to a method for treating, preventing or ameliorating a chronic neurodegenerative disorder, in particular progressive muscular atrophy (PMA), said method comprising administering to a subject in need of such a treatment, prevention or amelioration a specific inhibitor of a caspase I-dependent cytokine. Also specific inhibitors of a caspase I-dependent cytokine for treating, preventing or ameliorating a neurodegenerative disorder, in particular PMA, are disclosed herein. Furthermore, the present invention provides for the use of (a) specific inhibitor(s) of a caspase I-dependent cytokine in the medical or pharmaceutical intervention of neurodegenerative disorders. In particular said cytokine to be inhibited is selected from the group consisting of interleukin-1 (IL-1), interleukin-18 (IL-18), interleukin-33 and interferon γ (IFN-γ; interferon-gamma) and most preferably said inhibitor to be employed in context of this invention is a human interleukin-1 receptor antagonist (IL-1Ra), like anakinra. | 2010-12-09 |
| 20100310576 | COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES - Isolated aspartyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto. | 2010-12-09 |
| 20100310577 | METHODS FOR INCREASING THERMOGENIC ADIPOCYTES - In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes. | 2010-12-09 |
| 20100310578 | USE OF LIPOCALIN-2 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET - Methods and compositions for identifying and treating obesity and obesity-induced metabolic disorders are provided. One aspect provides a method for the evaluation of risk and progression of glucose tolerance, insulin resistance and Type 2 diabetes in mammalian subjects. The method includes measuring the concentration of circulating lipocalin-2 in a subject and comparing the measured level to lipocalin-2 to a reference level. Another aspect provides methods of treating insulin resistance, type 2 diabetes and other related complications by administering to a patient a composition that can reduce the circulating levels of lipocalin-2, for example a lipocalin-2 antagonist. | 2010-12-09 |
| 20100310579 | METHOD FOR INHIBITING ANGIOGENESIS OR FOR TREATMENT OF CANCER - The invention concerns a method for inhibiting angiogenesis or for treating or preventing cancer or cancer metastasis in an individual. The method is based on the administration of an agent capable of counteracting the influence of or for down-regulating the expression of the vascular adhesion protein 1 (VAP-I). The inhibition of the catalytic activity of VAP-I is especially desirable for inhibiting angiogenesis and for treating or preventing of cancer or cancer metastasis. | 2010-12-09 |
| 20100310580 | COMPOSITIONS AND METHODS FOR TREATING PRURITUS - The present invention encompasses methods and compositions for alleviating pruritis. The compositions may comprise an analgesic agent. | 2010-12-09 |
| 20100310581 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) - The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. | 2010-12-09 |
| 20100310582 | METHODS FOR INDUCING IN VIVO TOLERANCE - The present invention encompasses methods for inducing in vivo tolerance to a foreign tissue. | 2010-12-09 |
| 20100310583 | LET-7 MICRORNA AND MIMETICS THEREOF AS THERAPEUTICS FOR CANCER - The present invention relates to methods to treat or prevent cancers in a subject, in particular the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have reduced expression or are lacking in the cancer stem cells. In some embodiments, the miRNAs that are reduced or lacking in cancer stem cells are let-7 miRNAs. In alternative embodiments, the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have increased expression levels in the cancer stem cells. Another aspect of the present invention relates to methods to enrich for a cancer stem cell population. Another aspect of the present invention relates to methods to identify miRNAs which contribute to the self-renewal capacity of cancer stem cells. | 2010-12-09 |
| 20100310584 | Antigen - The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described. | 2010-12-09 |
| 20100310585 | THE USE OF MONOMYCOLYL GLYCEROL (MMG) AS AN ADJUVANT - Here we identify MMG and its alpha- and ketomycolic acid derivatives as highly bioactive lipids derived from | 2010-12-09 |
| 20100310586 | IDIOTYPIC VACCINE - The invention concerns the use of recombinant clonotypic immunoglobulins (Ig) as a vaccine in the treatment of HCV-related and non HCV-related lymphoproliferations, in particular the use of recombinant proteins with immunogenic properties derived from protein segments VK3-20 and VK3-15 of Ig light chains derived from patients with lymphoproliferations. | 2010-12-09 |
| 20100310587 | IMMUNOMODULATORY COMPOSITIONS - Methods useful, for example, in identifying plant compositions that have immunomodulatory activity. Also disclosed is an Asteraceae plant immunomodulatory composition useful for increasing an immune response, e.g., IFN γ or IL-2 transcription. | 2010-12-09 |
| 20100310588 | REGULATORY T CELLS SUPPRESS AUTOIMMUNITY - The invention provides methods for producing an autoantigen-specific regulatory T cell enriched composition, and resultant compositions and methods for use. | 2010-12-09 |
| 20100310589 | SWINE VACCINATION SYSTEM - A system for vaccinating swine according to one embodiment includes a housing having an open first end and an open opposite second end. The housing has a pair of side walls that are angled and non-parallel to one another such that at the second end only a single piglet can exit at one time. The system also includes a vaccination station for individually vaccinating piglets. The vaccination station is located between the pair of side walls in a region thereof that is sized to only permit one piglet to stand between the side walls. The vaccination station includes at least one sensor that detects the presence of the one piglet within the vaccination station and at least one spray nozzle positioned within the vaccination station such that a vaccine dose discharged therefrom is directed upwardly into facial areas of the piglet effectively. | 2010-12-09 |
| 20100310590 | HYPOALLERGENIC VARIANTS OF THE MAJOR ALLERGEN FROM BETULA VERRUCOSA POLLEN - The invention provides hypoallergenic variants of Bet v 2 major allergen from | 2010-12-09 |
| 20100310591 | Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA - The present invention provides an MHC class II antigen presentation enhancing hybrid polypeptide. The hybrid has an N-terminus comprising the mammalian Ii-key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and modifications thereof which retain antigen presentation enhancing activity, a C-terminus comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, and an intervening chemical structure covalently linking the N-terminal and C-terminal components. In a particular embodiment, the hybrid peptides of the present invention comprise influenza MHC class II epitopes identified herein as being effective in generating an immune response and provide immunity to the individual. | 2010-12-09 |
| 20100310592 | A TRUNCATED FORM OF THE HIV P17 PROTEIN - The invention relates to a truncated form of the HIV-1 p17 protein, designated as AT96, which consists of the residues from 1 to 96 of the full-length p17 protein, as well as the corresponding nucleic acid sequences. The truncated AT96 protein has the same immunological features as the full-length p17 protein but at the same time is devoid of the typical detrimental biological activities of the HIV-1 p17 protein. | 2010-12-09 |
| 20100310593 | Vaccines Against Chlamydia Infection - The present invention is directed to providing a vaccine to enhance the immune response of an animal in need of protection against a | 2010-12-09 |
| 20100310594 | RECOMBINANT ADENYLATE CYCLASE TOXIN OF BORDETELLA INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS - An immunogenic composition comprising a recombinant protein comprising a | 2010-12-09 |
| 20100310595 | METHOD OF TRANSFECTION AND COMPOSITIONS THEREFOR - The present invention relates to the targeted delivery of molecules to cells expressing toll-like receptors (TLRs). Aspects of the invention provide compounds comprising a positively charged group linked to a TLR ligand. These compounds are useful for in vitro and in vivo methods of transfection of TLR-expressing cells. Other aspects of the invention relate to the use of such compounds for repression of gene expression and DNA vaccination approaches. | 2010-12-09 |
| 20100310596 | Method and Compositions for Cutaneous Immunisation - The invention concerns the development of a system to deliver vaccines via cutaneous route. The invention more particularly concerns the use of a device comprising a condensation compartment for epicutaneous vaccination. The invention also concerns protocols for epicutaneous vaccination allowing an efficient immune response to be obtained without any skin treatment. The invention can be implemented in any mammal, preferably in human beings, to induce a therapeutic or preventive immune response against any type of antigen. | 2010-12-09 |
| 20100310597 | ANTI-OFLOXACIN MONOCLONAL ANTIBODY AND IMMUNOASSAY OF OFLOXACIN USING THE SAME - A method that accurately and conveniently detects a compound shown by the formula (I) in a human sample is disclosed. An antibody that reacts with the compound shown by the formula (I), but does not cross-react with the N-oxide metabolite and the desmethyl levofloxacin metabolite of the compound shown by the formula (I) is prepared using an antigen produced by binding bovine serum albumin to the compound shown by the formula (I) through the 6-position carboxyl group. | 2010-12-09 |
| 20100310598 | Extract of R. Miehei - Topical compositions comprising extracts of | 2010-12-09 |
